Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors’ reply

William J. Sandborn; Julian Panés; Bruce E. Sands; Walter Reinisch; Chinyu Su; Nervin Lawendy; Nana Koram; Haiyun Fan; Thomas V. Jones; Irene Modesto; Daniel Quirk; Silvio Danese

doi:10.1111/apt.15735

Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors’ reply

William J. Sandborn, Julian Panés, Bruce E. Sands, Walter Reinisch, Chinyu Su, Nervin Lawendy, Nana Koram, Haiyun Fan, Thomas V. Jones, Irene Modesto, Daniel Quirk, Silvio Danese

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	1209-1210
Number of pages	2
Journal	Alimentary Pharmacology and Therapeutics
Volume	51
Issue number	11
DOIs	https://doi.org/10.1111/apt.15735
State	Published - 1 Jun 2020

Access to Document

10.1111/apt.15735

Cite this

Sandborn, W. J., Panés, J., Sands, B. E., Reinisch, W., Su, C., Lawendy, N., Koram, N., Fan, H., Jones, T. V., Modesto, I., Quirk, D., & Danese, S. (2020). Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors’ reply. Alimentary Pharmacology and Therapeutics, 51(11), 1209-1210. https://doi.org/10.1111/apt.15735

@article{4b71aa7e3cc34213a2e7af0f6bfc8596,

title = "Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors{\textquoteright} reply",

author = "Sandborn, {William J.} and Julian Pan{\'e}s and Sands, {Bruce E.} and Walter Reinisch and Chinyu Su and Nervin Lawendy and Nana Koram and Haiyun Fan and Jones, {Thomas V.} and Irene Modesto and Daniel Quirk and Silvio Danese",

note = "Funding Information: These studies were sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461‐464). Funding Information: These studies were sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464). The authors' declarations of personal and financial interests are unchanged from those in the original article.1",

year = "2020",

month = jun,

day = "1",

doi = "10.1111/apt.15735",

language = "English",

volume = "51",

pages = "1209--1210",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

Sandborn, WJ, Panés, J, Sands, BE, Reinisch, W, Su, C, Lawendy, N, Koram, N, Fan, H, Jones, TV, Modesto, I, Quirk, D & Danese, S 2020, 'Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors’ reply', Alimentary Pharmacology and Therapeutics, vol. 51, no. 11, pp. 1209-1210. https://doi.org/10.1111/apt.15735

TY - JOUR

T1 - Letter

T2 - thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors’ reply

AU - Sandborn, William J.

AU - Panés, Julian

AU - Sands, Bruce E.

AU - Reinisch, Walter

AU - Su, Chinyu

AU - Lawendy, Nervin

AU - Koram, Nana

AU - Fan, Haiyun

AU - Jones, Thomas V.

AU - Modesto, Irene

AU - Quirk, Daniel

AU - Danese, Silvio

N1 - Funding Information: These studies were sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461‐464). Funding Information: These studies were sponsored by Pfizer Inc. Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications and was funded by Pfizer Inc, New York, NY, USA in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015;163:461-464). The authors' declarations of personal and financial interests are unchanged from those in the original article.1

PY - 2020/6/1

Y1 - 2020/6/1

UR - http://www.scopus.com/inward/record.url?scp=85085034466&partnerID=8YFLogxK

U2 - 10.1111/apt.15735

DO - 10.1111/apt.15735

M3 - Letter

C2 - 32424928

AN - SCOPUS:85085034466

SN - 0269-2813

VL - 51

SP - 1209

EP - 1210

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 11

ER -